病程中查血(血浆)EBV-DNA 10*4-10*5Copies/ml,影像学检查示双侧颈部及双侧咽后区多发淋巴结肿大,鼻咽软组织增厚,双侧腭扁桃体肿大;先后于多家医院行肿物活检及会诊,考虑为EBV阳性的T淋巴组织细胞增殖性疾病(I-II级,1年7月前)。入院查体:右侧颈部可...
今日消息,威斯津生物在全球首次启动了治疗EBV病毒相关恶性肿瘤的mRNA疫苗药物的注册临床试验。 根据clinicaltrials.gov网站显示,一项名为“Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors...
mRNA疫苗由威斯津生物的联合创始人宋相容教授牵头研发,历时长达5年。部分研究成果于2013年1月已发表于国际期刊Nano Research,题名为:A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma。动物试验研究显示,mRNA疫苗可显著抑制针EBV阳性肿瘤细胞的生长,安全性较好。 EBV属于疱疹病毒科γ亚科的dsDNA病毒,...
Another vaccine that researchers are studying produced a strong immune response against EBV in mice. Whether it will work in humans still has to be proved. Right now, the best way to avoid the virus is to stay away from anyone who you know is infected, and especially someone who has mono...
scientific founder in cellular therapy support broad applicability of the AMP platform. Our near-term focus, however, remains progressing ELI-002, our cancer vaccine candidate for mutant KRAS-driven solid tumors, through the ongoing phase 1 trials and to a randomized trial in pancreatic cancer in ...
From 2006 to 2015, several clinical trials were conducted to develop vaccines; however, an EBV vaccine, phase 2 trial, from gp350 protein has been testified. This vaccine reduced the rate of Infectious Mononucleosis (IM) but not virus infection7. Precautionary measures, such as avoiding direct ...
The vaccine, named HepaVac-101, showed a favourable safety profile and moderate immunogenicity [74]. CV8102 trials have been expanded to evaluate antitumour response in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid ...
Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC), and provides a target for a dendritic cell (DC) vaccine. CD137 ligand (CD137L)
mRNA疫苗由威斯津生物的联合创始人宋相容教授牵头研发,历时长达5年。部分研究成果于2013年1月已发表于国际期刊Nano Research,题名为:A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma。动物试验研究显示,mRNA疫苗可显著抑制...
This general observation leads to multiple clinical trials aiming at de-intensifying treatments for HPV(+) HNSCC. Although the HPV vaccine has been shown to be effective for the prevention of cervical cancer, and its impact on HPV(+) HNSCC is currently being validated with promising preventive ...